Combining targeted radiation with immunotherapy and chemotherapy for advanced laryngeal and hypopharyngeal cancer
SBRT Followed by Chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin for Larynx Preservation in Patients with Locally Regionally Advanced Squamous Cell Carcinoma of the Larynx and Hypopharynx
This study is testing a new treatment that combines targeted radiation with immunotherapy and chemotherapy to see if it can help people with advanced laryngeal and hypopharyngeal cancer while preserving their voice box.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 35 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | Sun Yat-sen University Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy, Toripalimab |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT06611137 on ClinicalTrials.gov |
What this trial studies
This trial evaluates the safety and effectiveness of stereotactic body radiation therapy (SBRT) followed by a combination of the immunotherapy drug Toripalimab and chemotherapy agents Docetaxel and Cisplatin in patients with locally advanced squamous cell carcinoma of the larynx and hypopharynx. The study aims to preserve the larynx while effectively treating the cancer. Participants will be monitored for treatment response and side effects throughout the trial. The approach combines innovative radiation techniques with cutting-edge immunotherapy and chemotherapy.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18-70 with locally advanced laryngeal or hypopharyngeal cancers who are in good health and can tolerate the proposed treatments.
Not a fit: Patients with other malignant tumors or contraindications to immunotherapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could improve survival rates and preserve the larynx in patients with advanced laryngeal and hypopharyngeal cancers.
How similar studies have performed: Other studies have shown promising results with similar combinations of immunotherapy and chemotherapy in treating advanced cancers, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Laryngeal (T3-4N0-3M0 ) and hypopharyngeal ( T2-4N0-3M0) cancers staged by AJCC8th * age 18-70 * PS score 0-1 * normal functions to tolerate chemotherapy, immunotherapy and radiotherapy Exclusion Criteria: * Patients with a combination of other malignant tumours * Individuals with contraindications to immunotherapy
Where this trial is running
Guangzhou, Guangdong
- Sun Yat-sen University Cancer Center — Guangzhou, Guangdong, China (Recruiting)
Study contacts
- Study coordinator: Fang-Yun Xie
- Email: xiefy@sysucc.org.cn
- Phone: +8613902205880
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.